Industry
Reports
Healthcare
سوق Biguanide في الشرق الأوسط وأفريقيا - مقسمًا حسب الأدوية والجغرافيا - النمو و ...
1. Introduction
1.1 Scope of Study
1.2 Market Definition
1.3 Executive Summary
2. Research Methodology
2.1 Study Deliverables
2.2 Study Assumptions
2.3 Research Phases
3. Market Insights
3.1 Technology Trends
3.2 Industry Attractiveness - Porter's Five Forces Analysis
3.2.1 Bargaining Power of the Suppliers
3.2.2 Bargaining Power of the Consumers
3.2.3 Threat of New Entrants
3.2.4 Threat of Substitute Products and Services
3.2.5 Competitive Rivalry within the Industry
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
5. Market Indicators
5.1 Total Diabetes Population
5.2 Type 2 Diabetes Population
6. Market Segmentation and Analysis
6.1 By Drug
6.1.1 Metformin
6.1.1.1 Metformin, Revenue (2012-2023)
6.1.1.2 Metformin, Volume (2012-2023)
7. Geographical Analysis
7.1 Middle East & Africa
7.1.1 South Africa
7.1.1.1 South Africa, Revenue (2012-2023)
7.1.1.2 South Africa, Volume (2012-2023)
7.1.2 Saudi Arabia
7.1.2.1 Saudi Arabia, Revenue (2012-2023)
7.1.2.2 Saudi Arabia, Volume (2012-2023)
7.1.3 Oman
7.1.3.1 Oman, Revenue (2012-2023)
7.1.3.2 Oman, Volume (2012-2023)
7.1.4 Egypt
7.1.4.1 Egypt, Revenue (2012-2023)
7.1.4.2 Egypt, Volume (2012-2023)
7.1.5 Iran
7.1.5.1 Iran, Revenue (2012-2023)
7.1.5.2 Iran, Volume (2012-2023)
7.1.6 Rest of Middle East and Africa
7.1.6.1 Rest of Middle East and Africa, Revenue (2012-2023)
7.1.6.2 Rest of Middle East and Africa, Volume (2012-2023)
8. Key Player Profiles
8.1 Bayer
8.2 Mylan
8.3 Teva
8.4 Takeda
8.5 Ranbaxy/Sun Pharma
8.6 Actavis
8.7 GlaxoSmithKline
8.8 Merck
8.9 Bristol-Myers Squibb
8.10 Boehringer Ingelheim Pharmaceuticals
* Each Company Profile include overview, Revenue, Product and services, Swot, Recent Activities and strategic Analysis.
